Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Viemed Healthcare Inc VMD

Viemed Healthcare, Inc. through its subsidiaries, is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counselling to patients in their homes using cutting edge technologies. The Company’s products and services include Home Medical Equipment, In-home sleep testing, and Healthcare staffing. Home Medical Equipment provides respiratory and other home medical equipment, including home ventilation, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) devices, percussion vests, and other medical equipment. In-home sleep testing provides in home sleep apnea testing services. Healthcare staffing provides healthcare staffing and recruitment services. The Company provides home medical equipment services through its interest in East Alabama HomeMed, LLC (HomeMed).


NDAQ:VMD - Post by User

Bullboard Posts
Comment by MBAon Aug 10, 2018 10:59am
255 Views
Post# 28440517

RE:I think maybe today....

RE:I think maybe today....Agree, but a combination of SIS's numbers coming out and ..... - been consolidating for months around $4.40 to $4.60. Time to move to a new trading range which should be higher due to the financials coming out - we are now virtually half way through Q3 and guidance should be in the 61 cent a share range for the current quarter. Even a 10x multiple means the SP should be north of $6 based on current run rate, but most stocks trade at multiples based on excepted next year numbers which should be north of 75 cents a share. So based on this, the stock is extremely undervalued and should be trading well over $7 and as high as $9 based on next year's expected numbers and a 12x multiple. - then there is the potential for cost sharing agreements so even more upside potential. Q2 numbers should come in at $15.3 revenue (up 40% from Q2, 2017) and $4.13 EBITDA (up 72% from Q2, 2017). Still smiling and glad I was accumulating more in the $4's.
Bullboard Posts